into sufficiently conditioned recipients is an effective experimental approach for the induction of transplantation tolerance. Clinical translation, however, is impeded by the lack of feasible protocols devoid of cytoreductive conditioning (i.e. irradiation and cytotoxic drugs/mAbs). The therapeutic application of regulatory T cells (Tregs) prolongs allograft survival in experimental models, but appears insufficient to induce robust tolerance on its own. We thus investigated whether mixed chimerism and tolerance could be realized without the need for cytoreductive treatment by combining Treg therapy with BM transplantation (BMT). Polyclonal recipient Tregs were cotransplanted with a moderate dose of fully mismatched allogeneic donor BM into recipients conditioned solely with short-course costimulation blockade and rapamycin. This combination treatment led to long-term multilineage chimerism and donor-specific skin graft tolerance. Chimeras also developed humoral and in vitro tolerance. Both deletional and nondeletional mechanisms contributed to maintenance of tolerance. All tested populations of polyclonal Tregs (FoxP3-transduced Tregs, natural Tregs and TGF-b induced Tregs) were effective in this setting. Thus, Treg therapy achieves mixed chimerism and tolerance without cytoreductive recipient treatment, thereby eliminating a major toxic element impeding clinical translation of this approach.
Introduction

Outcome after organ transplantation could be improved through the establishment of donor-specific immunological tolerance. Rodent models of tolerance through mixed chimerism are among the most robust and are thus attractive candidates for clinical development (1-8). The exceptional clinical potential of the mixed chimerism approach has recently been underscored by a pilot series of renal transplant recipients cotransplanted with donor BM who accepted their organ graft in most cases without maintenance immunosuppression (9). Routine clinical application of this approach, however, is prevented by the toxicity of the cytoreductive recipient conditioning which is required to allow even transient engraftment of MHC-mismatched BM.
Since the concept's introduction with myeloablative conditioning (10) , gradually less toxic murine mixed chimerism regimens have been developed. However, the induction of durable mixed chimerism in robust strain combinations has universally required either recipient irradiation (2, 3, 6, 11) , cytotoxic drug/antibody treatment (8, 12, 13) or clinically unobtainable high doses of BM (4, 14, 15) . As irradiation and cytotoxic drugs are associated with considerable medical risks such as profound leukopenia (9) 
, their elimination from tolerance protocols is widely regarded as essential for widespread clinical translation. This goal of a noncytoreductive mixed chimerism model with conventional BM doses has remained elusive so far.
Tregs play a critical role in maintaining self-tolerance. The therapeutic exploitation of Tregs has pronounced effects in autoimmune (16) , organ transplantation (17, 18) and GVHD models (19, 20) , but does not induce skin graft tolerance across full MHC barriers on its own (11, 17) , which is regarded as a stringent test in rodent models. Numerous naturally occurring and experimentally designed subsets of Tregs have been described that are being considered for clinical application (21 (22, 23) . Although the role of FoxP3 in humans is more complex (24) (25, 26) . Natural CD4
, lentiviral transduction of FoxP3 has recently allowed generation of stable human Tregs (23). Induction of Tregs through in vitro exposure of murine T cells to TGF-b (iTregs) likewise allows the production of large quantities of Tregs
+ CD25 + Tregs (nTregs) are currently already under evaluation in several clinical trials (27) . Figure 2A -C) (6) and positively affects Treg function in vitro and in vivo (30) (31) (32) Figure 2D) . Thus, the combination of Tregs with rapamycin-but not either alone-allowed BM engraftment without cytoreduction. (33 
We therefore investigated the therapeutic potential of several populations of Tregs (FoxP3-Tregs, nTregs and iTregs) to induce engraftment of conventional doses of allogeneic BM, mixed chimerism and transplantation tolerance without cytoreductive recipient conditioning.
Materials and Methods
Animals
Antidonor antibodies
Chimerism in Treg-treated BMT recipients was of multilineage nature, with donor populations present in all tested leukocyte lineages, including CD4 and CD8 cells (Figure 3A-C). Chimerism levels in peripheral blood correlated with chimerism in lymphoid organs (BM and spleen, data not shown). Multilineage chimerism persisted for the length of follow up (>5 months post-BMT), suggesting that donor hematopoietic stem cells had successfully engrafted and survived in recipient mice
lineage was assessed by flow cytometry of peripheral blood at multiple time points and is shown as mean percent (error bars indicate standard deviation; nTreg and iTreg groups were done in the same experiment, therefore the control group is shown twice in B + C). Repeat experiments performed with nTregs and iTregs showed similar results. * * p < 0.005, * p < 0.05 with versus without Tregs (two-sided Student's t-test). (D) B6 mice received 2 × 10 7 Balb/c BM cells under the cover of costimulation blockade and 5 × 10 6 iTregs with or without rapamycin. Recipients treated without rapamycin failed to develop chimerism (• iTregs with rapamycin n = 8; iTregs without rapamycin, n = 8; p = 0.0002, Fisher's exact test). Donor (H-2D d+ ) chimerism among leukocytes of the myeloid (Mac1 + ) lineage is shown 2 weeks post-BMT as scatter plot (mean and standard deviation are indicated).
Chimeras induced through Treg treatment show humoral and in vitro tolerance
Development of antidonor Abs (antibodies) is associated with the occurrence of chronic rejection and late graft loss in clinical transplantation and suggests incomplete tolerance in the experimental setting (34). Hence we tested BMT recipients for the presence of antidonor antibodies early (1 and 2 weeks) and late (>3 months) after BMT through flow cytometric assessment of recipient serum binding to donor cells. No antidonor Abs were detectable in chimeras treated with Tregs at any time point, whereas control mice (BMT recipients receiving the same regimen without Tregs) developed substantial levels of antidonor Abs at late time points (data not shown). Thus, Treg-treatment prevents development of a humoral antidonor response in BMT recipients.
To further characterize the state of tolerance, in vitro MLR assays were performed. Hyporesponsiveness toward the Figure 4D ) and was reduced to the level of self-reactivity during long-term follow-up ( Figure 4E) 
in Treg-treated mice was of multilineage nature as shown by the presence of donor cells among the T-cell (CD4, CD8), B-cell (B220) and myeloid (Mac1) lineages. Two-color flow cytometry plots are shown from representative BMT recipients ∼3 months post-BMT treated with (A) FoxP3-Tregs, (B) nTregs and (C) iTregs. (D) BM was recovered from iTreg-treated chimeras (8 weeks post-BMT; n = 3) and transplanted into myoablated secondary B6 recipients. Donor chimerism was detectable in the T-cell (CD4, CD8), B-cell (B220) and myeloid (Mac1) lineages 12 weeks postsecondary BMT, indicating that donor hematopoietic stem cells had engrafted in primary recipients. Flow cytometry plots are shown from one secondary recipient. Numbers indicate the net percentage of donor chimerism in the depicted lineage (for calculation algorithm, please see section 'Materials and Methods'). donor was observed already 1 week post-BMT in Tregtreated recipients (
Intra-graft frequencies of mast cells and Tregs are increased in Treg-treated chimeras In the Treg groups, donor skin grafts remained macroscopically intact for the length of follow up. Histopathological analysis at the end of the observation period showed an
Tregs for Noncytoreductive Mixed Chimerism tolerance does not depend on regulation (36) (mean density of mast cells [5 HPF counted] 28.6, n = 7, vs. 17.9, n = 3 controls, p = 0.0467; Student's t-test) ( Figure 5A ). Figure  5A) 
Donor-specific tolerance was assessed by grafting of full thickness donor and third party (C3H) tail skin 4-6 weeks post-BMT. Grafts were considered to be rejected when less than 10% remained viable. Donor skin graft survival was significantly prolonged in BMT recipients treated with (A) FoxP3-Tregs ( , n = 7; p = 0.0002) compared to BMT recipients without Tregs ( , n = 6); and in recipients treated with (B) nTregs ( , n = 4; p = 0.0360) and (C) iTregs ( , n = 6; p = 0.0043) compared to the controls without Tregs ( , n = 7, same control group for B + C). Third-party grafts were promptly rejected in all groups (Treg-treated •, control ). Survival was calculated according to the Kaplan-Meier product limit method and compared between groups using the log-rank test. Repeat experiments performed with nTregs and iTregs showed similar results. (D,E) Mixed lymphocyte reaction results from selected BMT recipients were obtained early (1 week post-BMT) and at the end of follow-up (22 weeks post-BMT). (D) Early MLRs (1 week post-BMT) demonstrate hyporesponsiveness toward the donor in Treg-treated recipients (n = 2) in comparison to controls without Tregs (p = 0.0120, SI antidonor compared to controls). (E) Long-term chimeras of Treg-treated mice (nTreg, n = 2; iTreg, n = 3) showed specific hyporesponsiveness toward the donor in vitro (p = 0.0446 for nTregs; p = 0.0063 for iTregs, SI antidonor compared to naïve B6 mice). SIs were calculated by dividing the mean cpm from responses against recipient (black column; B6), donor (white column; Balb/c), or third-party (gray column; C3H) stimulator cells by mean background cpm (i.e. cpm with no stimulator population). Error bars indicate standard deviation. intact epidermis without lymphocytic infiltrates, intact skin adnexa and weak-to-moderate lymphocytic infiltrates in the dermis. Donor grafts of Treg-treated chimeras were remarkable for an abundance of mast cells, which have been linked to Treg-mediated tolerance (35). The frequency of graft-infiltrating mast cells was significantly increased in Treg-treated mice over tolerant chimeras induced with a nonmyeloablative regimen in which maintenance of
As immunohistochemistry also revealed substantial numbers of FoxP3 positive cells within donor grafts (37) (
Chimeras induced through Treg treatment demonstrate partial central and peripheral deletion of donor-reactive T cells Depending on the specifics of the chimerism model, both deletional (central and peripheral) and nondeletional mechanisms contribute to tolerance to varying
Tregs for Noncytoreductive Mixed Chimerism (7, 36, 38) [39] ) and hence is a useful surrogate marker to measure whether deletion occurs (3, 4 Figure 6B ). 
. In chimeras, the frequency of certain superantigen-reactive T-cell populations correlates with the deletion of 'truly alloreactive', donor-specific CD4 cells (as it can be assessed directly by employing TCR-transgenic T cells recognizing donor MHC
Central deletion was also directly evident among thymocytes of Treg-treated long-term chimeras (22 weeks post-BMT) (Figure 6C
)
